Free cash flow remains consistently negative, with quarterly outflows reaching as high as $6.8 million in 2025Q3, necessitating continuous external financing to maintain operations.
| Cash from Operations | -23.41M | -22.78M | -10.25M | -4.16M | -1.06M | -1.45M |
| Operating CF Margin % | - | - | - | - | - | - |
| Operating CF Growth % | -338.69% | -122.27% | -146.43% | -293.36% | 27% | - |
| Net Income | -36.93M | -35.44M | -11.16M | -5.31M | -1.69M | -2.06M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 117.45K | 1.51M | 713.12K | 98.58K | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 12.5M | 10.75M | 162.24K | 584.82K | 713.97K | 613.88K |
| Working Capital Changes | -1.4M | 407.7K | 32.93K | 473.1K | -78.69K | -6.66K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -250.96K | 0 | 808.75K | 79.09K | 0 | 0 |
| Cash from Investing | -4.65M | -4.62M | 0 | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - |
| Acquisitions | 0 | -4.62M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | -4.65M | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 31.16M | 31.94M | 12.69M | 5.61M | 1.25M | 882.38K |
| Debt Issued (Net) | 2.55M | 3.1M | 5.17M | 500K | 1.25M | 882.38K |
| Equity Issued (Net) | 27.68M | 19.75M | 7.52M | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 926.68K | 9.08M | 0 | 5.11M | 0 | 0 |
| Net Change in Cash | 3.02M | 4.54M | 2.44M | 1.45M | 189.14K | -565.66K |
| Free Cash Flow | -23.41M | -22.78M | -10.25M | -4.16M | -1.06M | -1.45M |
| FCF Margin % | - | - | - | - | - | - |
| FCF Growth % | -83.01% | -122.27% | -146.43% | -293.36% | 27% | - |
| FCF per Share | -0.79 | -1.32 | -1.07 | -0.83 | -0.13 | -0.18 |
| FCF Conversion (FCF/Net Income) | 0.63x | 0.90x | 0.92x | 0.78x | 0.62x | 0.70x |
| Interest Paid | 0 | 0 | 40.56K | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical trial funding dependency
As reported in quarterly financial filings, Medicus Pharma exhibits a volatile relationship between net income and operating cash flow, with OCF/NI ratios fluctuating between 0.43 and 1.34, suggesting that non-cash adjustments and working capital swings significantly distort the underlying cash consumption profile of the clinical-stage entity.
The wide variance in the OCF/NI ratio indicates that net income is a poor proxy for the actual cash burn required to sustain the SkinJect development program. Investors should monitor these discrepancies, as they often reflect the timing of clinical trial payments rather than core operational efficiency.
Based on the company's reported figures, free cash flow remains consistently negative, with quarterly outflows ranging from $1.2 million to $6.8 million, highlighting the structural reliance on external financing to support the ongoing Phase II clinical trials for the firm's lead dermatological asset.
The absence of positive free cash flow is expected for a pre-revenue biotech, yet the trend shows no signs of stabilization as clinical intensity increases. This trajectory suggests that the company will likely require additional capital infusions to reach commercialization, potentially leading to further shareholder dilution.
According to recent SEC filings, working capital changes have been highly erratic, swinging from a $1.4 million outflow in 2025Q3 to a $1.0 million inflow in 2025Q1, which complicates the predictability of the company's short-term cash runway and overall liquidity management during critical trial phases.
These fluctuations likely stem from the timing of vendor payments and CRO milestones rather than operational improvements. Such volatility warrants investigation, as it may mask the true underlying burn rate required to maintain the current clinical development schedule.
As noted in financial statements, the cash flow statement obscures the true cost of development by excluding significant stock-based compensation and potential off-balance-sheet commitments, which, when combined with the reported $8.7 million cash position, suggests a limited window for continued operations without further capital raises.
The reliance on non-cash adjustments to reconcile net income to operating cash flow may lead investors to underestimate the actual cash requirements of the business. The current cash position appears insufficient to support long-term development, necessitating a close watch on future financing activities.
Quick answers to the most common questions about buying MDCXW stock.
Medicus Pharma Ltd. (MDCXW) generated $-22.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Medicus Pharma Ltd. (MDCXW) reported negative free cash flow of $22.8M in 2025, indicating capital requirements exceeded cash from operations.
Medicus Pharma Ltd. (MDCXW) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.